You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company anticipates launching an in vitro diagnostic version of the 10-gene ThyroidPrint assay in South America and Europe after receiving regulatory clearance by Q2 2021.
The Parsippany, New Jersey-based firm expects to expand relationships with multiple biopharmaceutical companies after bolstering its biopharma services business.
Palmetto has expanded the local coverage determination for the Guardant360 liquid biopsy assay to be used with the majority of advanced solid tumors.
Of the 28 companies in the index, 21 companies' share prices increased while the share values of 7 declined month over month.
The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.
The new name better reflects its business model combining MDx testing with the drug discovery and development services business it acquired from Cancer Genetics.
Under the new 15-year exclusive agreement, the test will become available through all of Sonic's clinical labs and anatomic pathology practices in the US.
The method uses DESI-MS imaging to analyze fine-needle aspiration biopsies and could help evaluate cases where traditional cytology is inconclusive.
When used together, ThyGeNext and ThyraMir combine next-generation sequencing of an individual's DNA and RNA along with a microRNA classifier.
The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.